Deverra Therapeutics
Seattle, US · Founded 2019 · Delaware corporation
Founders & leadership
CD
Colleen DelaneyNamed on SEC filing
MW
Michael W YurkowskyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 2 rounds · 2020–2023
▶$2.4MraisedSep 2023 · 1 investors · BiotechnologyRule 506(b)
▶$2.4MraisedSep 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael YurkowskyExecutive Officer
- Colleen DelaneyExecutive Officer
- Offering amount
- $2.4M
- Amount sold
- $2.4M
- Minimum investment
- $2.4M
- Sales commissions
- $80K
- Placement agents
- RBC Capital Markets
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b, 3C, 3C.1
▶$75KraisedAug 2020 · 2 investors · BiotechnologyRule 506(b)
▶$75KraisedAug 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colleen DelaneyExecutive Officer
- Michael W YurkowskyExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $75K
- Minimum investment
- $25K
- Sales commissions
- $210K
- Placement agents
- Silverwood Partners, Silverwood Partners
- First sale
- Aug 2020
- Incorporated
- Corporation, Minnesota, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Deverra Therapeutics raised?
- Deverra Therapeutics has disclosed $2.5M raised across 2 rounds.
- Where is Deverra Therapeutics headquartered?
- Deverra Therapeutics is headquartered in Seattle, US.